Curis Inc(CRIS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:37 PM ET (Korea 10/31 08:37)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -14.29 | Insider Own | 17.07% | Shs Outstand | 1.9M | Perf Week | 55.32% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 87.24% | Insider Trans | - | Shs Float | - | Perf Month | -27.77% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -2.67 | Inst Own | 32.4% | Short Float | - | Perf Quarter | -88.35% |
| Income | -0.02B | P/S | 0.93 | EPS this Y | -306.38% | Inst Trans | -10.02% | Short Ratio | 1.29 | Perf Half Y | -94.93% |
| Sales | 0.00B | P/B | 0.25 | EPS next 5Y | 15.9% | ROA | -87.76% | Short Interest | 0.44M | Perf YTD | -96.96% |
| Book/sh | 2.41 | P/C | 0.71 | EPS past 3/5Y | 63.8% 45.78% | ROE | -693.93% | 52W High | -98.11% ($31.80) | Perf Year | -97.99% |
| Cash/sh | 0.84 | P/FCF | - | Sales past 3/5Y | -2.42% -2.71% | ROIC | -450.54% | 52W Low | 84.62% ($0.32) | Perf 3Y | -99.28% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.37% | Gross Margin | 97.71% | Volatility(W/M) | 25.29% 17.35% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | -0.13 | Sales Y/Y TTM | -62.17% | Oper. Margin | -833.4% | ATR (14) | 0.1 | Perf 10Y | -99.99% |
| Dividend Ex-Date | - | Quick Ratio | 0.49 | EPS Q/Q | 70.48% | Profit Margin | -490.33% | RSI (14) | 42.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.49 | Sales Q/Q | -100% | SMA20 | 11.37% ($0.54) | Beta | 3.24 | Target Price | $42.67 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/07/30 | SMA50 | -34.86% ($0.92) | Rel Volume | 2.69 | Prev Close | $0.55 |
| Employees | 24 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 40.38% -100% | SMA200 | -93.36% ($9.04) | Avg Volume(3M) | 0.34M | Price | $0.6 |
| IPO | 2000/8/1 | Option/Short | No/No | Trades | 1773 | Volume | 915,541 | Change | 9.39% |
🩸 Curis() is a clinical-stage oncology biotech with IRAK4 inhibitor emavusertib (CA-4948) as its core pipeline. The company focuses on hematologic cancers such as acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), and primary central nervous system lymphoma (PCNSL), and generates partial revenue from a royalty on Genentech/Roche's Erivedge.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded more than usual. That is 269% of its average volume.
CRIS has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -306.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $93. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 32.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #550 of 597 in the industry
Based on market cap of $4M.
FAQ
What kind of company is CRIS?
CRIS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRIS?
The market cap of CRIS is approximately $4M, ranking 5,666 within its sector.
What is the 52-week high and low for CRIS?
CRIS has recorded a 52-week high of $31.80 and a low of $0.32.
